These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31641350)

  • 41. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy.
    Ballerini MG; Braslavsky D; Scaglia PA; Keselman A; Rodríguez ME; Martínez A; Freire AV; Domené HM; Jasper HG; Bergadá I; Ropelato MG
    Horm Res Paediatr; 2017; 88(5):354-363. PubMed ID: 28926833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children.
    Hou L; Liang Y; Wu W; Lin HH; Luo XP; Ying YQ
    Growth Horm IGF Res; 2020; 53-54():101331. PubMed ID: 32777706
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.
    Romer T; Peter F; Saenger P; Starzyk J; Koehler B; Korman E; Walczak M; Wasik R; Ginalska-Malinowska M; Solyom E; Berghout A
    J Endocrinol Invest; 2007; 30(7):578-89. PubMed ID: 17848841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
    Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
    J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment.
    Soliman A; Rogol AD; Elsiddig S; Khalil A; Alaaraj N; Alyafie F; Ahmed H; Elawwa A
    J Pediatr Endocrinol Metab; 2021 Oct; 34(10):1263-1271. PubMed ID: 34291621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of recombinant human growth hormone therapy on blood lipid and carotid intima-media thickness in children with growth hormone deficiency.
    Chen M; Gan D; Luo Y; Rampersad S; Xu L; Yang S; Li N; Li H
    Pediatr Res; 2018 May; 83(5):954-960. PubMed ID: 29206809
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Gomez R; Khadilkar V; Shembalkar J; Chu DM; Ko CW; Wajnrajch MP; Wang R
    J Pediatr Endocrinol Metab; 2024 Jun; 37(6):525-531. PubMed ID: 38717038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency.
    Janssen YJ; Doornbos J; Roelfsema F
    J Clin Endocrinol Metab; 1999 Jan; 84(1):279-84. PubMed ID: 9920096
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype.
    Azcona C; Preece MA; Rose SJ; Fraser N; Rappaport R; Ranke MB; Savage MO
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):787-92. PubMed ID: 10619985
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-acting PEGylated growth hormone in children with idiopathic short stature.
    Luo X; Zhao S; Yang Y; Dong G; Chen L; Li P; Luo F; Gong C; Xu Z; Xu X; Gong H; Du H; Hou L; Zhong Y; Shi Q; Chen X; Chen X; Xu L; Cheng R; Su C; Ma Y; Xu L; Zhang L; Lu H
    Eur J Endocrinol; 2022 Nov; 187(5):709-718. PubMed ID: 36130048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The long-term growth, cost-effectiveness, and glycemic effects of growth hormone therapy on children born small for gestational age over 10 years: a retrospective cohort study.
    Al Khalifah RA; Alhakami A; AlRuthia Y; Al Sarraj HZ; Abulqasim J; Al-Rasheedi A; NurHussen A; Naji A
    J Pediatr Endocrinol Metab; 2022 Nov; 35(11):1357-1368. PubMed ID: 36203313
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TNF-alpha levels in children with growth hormone deficiency and the effect of long-term growth hormone replacement therapy.
    Andiran N; Yordam N
    Growth Horm IGF Res; 2007 Apr; 17(2):149-53. PubMed ID: 17314057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal final adult height achieved by low-dose recombinant human growth hormone therapy.
    Saengkaew T; Aroonparkmongkol S; Wacharasindhu S
    Asian Biomed (Res Rev News); 2024 Apr; 18(2):53-60. PubMed ID: 38708332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency.
    Zavras N; Meazza C; Pilotta A; Gertosio C; Pagani S; Tinelli C; Bozzola M
    Ital J Pediatr; 2015 Oct; 41():71. PubMed ID: 26444854
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant hGH replacement therapy and the hypothalamus-pituitary-thyroid axis in children with GH deficiency: when should we be concerned about the occurrence of central hypothyroidism?
    Giavoli C; Porretti S; Ferrante E; Cappiello V; Ronchi CL; Travaglini P; Epaminonda P; Arosio M; Beck-Peccoz P
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):806-10. PubMed ID: 14974926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prediction of response to growth hormone treatment in pre-pubertal children with growth hormone deficiency.
    Valle D; Bartolotta E; Caruso M; De Sanctis C; Falorni A; Saggese G; Pasquino AM; Tauchmanova L; Cicognani A
    J Endocrinol Invest; 2011 Jun; 34(6):e126-30. PubMed ID: 21042043
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency.
    Søndergaard E; Klose M; Hansen M; Hansen BS; Andersen M; Feldt-Rasmussen U; Laursen T; Rasmussen MH; Christiansen JS
    J Clin Endocrinol Metab; 2011 Mar; 96(3):681-8. PubMed ID: 21177789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
    Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences in Response to Recombinant Growth Hormone Therapy on Height Gain in Patients with Idiopathic Short Stature Vs. Patients with Growth Hormone Deficiency.
    Alzahrani AK; Algethami AK; Barnawi G; Meftah IA; Alshanqiti A; Al-Hashmi H; Khan MA; Felimban N
    Cureus; 2020 Mar; 12(3):e7319. PubMed ID: 32313760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Basal characteristics and first year responses to human growth hormone (GH) vary according to diagnostic criteria in children with non-acquired GH deficiency (naGHD): observations from a single center over a period of five decades.
    Ranke MB; Schweizer R; Binder G
    J Pediatr Endocrinol Metab; 2018 Nov; 31(11):1257-1266. PubMed ID: 30332395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.